Flaviano Giorgini

A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease

Paolo Guidetti, F. Giorgini, P. Muchowski, 2005, Nature Genetics.

Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in Huntington's disease

Edward J. Hollox, Tiago F. Outeiro, Michael Orth, 2014, Human molecular genetics.

Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntington’s disease models

Timothy W. Gant, J. L. Smalley, Ruth Luthi-Carter, 2015, Journal of Molecular Medicine.

Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites

Charalambos P. Kyriacou, Francesca M. Notarangelo, R. Schwarcz, 2016, Proceedings of the National Academy of Sciences.

A network of protein interactions determines polyglutamine toxicity.

Susan Lindquist, Smitha Jagadish, Martin L. Duennwald, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition)

Sangeeta Khare, Xin Qi, Ying Wang, 2016 .

α-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner

Christian Griesinger, Stefan Becker, Roger S. Goody, 2014, Neurobiology of Disease.

Choosing and using Drosophila models to characterize modifiers of Huntington's disease.

Edward W Green, F. Giorgini, E. W. Green, 2012, Biochemical Society transactions.

L18 Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites

Charalambos P. Kyriacou, Francesca M. Notarangelo, R. Schwarcz, 2016 .